SCHEMBL6490563

SCHEMBL6490563

CCCCCOc1ccc(Cn2c(C)nc3ccc(-c4nc(C)c(C(=O)O)o4)cc32)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.45
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.38
ALOX5AP P20292 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
VDR P11473 2/20 0.37
NR1H4 Q96RI1 2/20 0.37
PLA2G2A P14555 1/20 0.37
PTPN11 Q06124 1/20 0.36
PIN1 Q13526 1/20 0.36
DHODH Q02127 1/20 0.36
PDE6D O43924 1/20 0.36
PDE2A O00408 3/20 0.36
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488200 0.93 PPARG (0.43) PPARGMAPTBRD4ALOX5APKDM4E
SCHEMBL6497985 0.88 PPARG (0.36) PPARGMAPTALOX5APKDM4ENPC1
SCHEMBL6491906 0.85 PPARG (0.45) PPARGBRD4ALOX5APKDM4ENPC1
SCHEMBL6301607 0.84 PPARG (0.58) PPARGPTPN11
SCHEMBL6303646 0.84 PPARG (0.57) PPARGPTPN11
SCHEMBL6308005 0.84 PPARG (0.57) PPARGPTPN11
SCHEMBL6303584 0.84 PPARG (0.56) PPARGALOX5APVDRNR1H4PIN1
SCHEMBL6487612 0.82 PPARG (0.51) PPARGALOX5AP
SCHEMBL6498744 0.82 PPARG (0.51) PPARGMAPTALOX5APPLA2G2APDE2A
SCHEMBL6491422 0.82 PPARG (0.51) PPARGALOX5APPLA2G2APDE2APPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885MAPT 3168/4885BRD4 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.